Literature DB >> 26617804

Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.

Yuanxun Yang1, Yan Jin2, Wenxi Du3.   

Abstract

OBJECTIVES: To investigate the role of programmed cell death 2 (PDCD2) in osteosarcoma (OS), along with correlations between PDCD2 and CD4(+)/CD8(+).
METHODS: Sprague-Dawley (SD) rats were randomly assigned to control group and OS group. The OS group rats were subjected to induce models of OS by transplantation with UMR106 cells. Peripheral blood was collected to test the percentages of the CD4(+) and CD8(+) cell subsets using flow cytometry (FCM). Western blotting was performed to determine the PDCD2 protein level. The correlations between PDCD2 and CD4(+)/CD8(+) were analyzed by Pearson correlation coefficient. Besides, specific small interfering RNAs (siRNA) against PDCD2 and nonspecific (NS)-siRNA were transfected into UMR106 cells. Cell viability and invasive ability were determined after transfection.
RESULTS: CD4(+) cells percentages were significantly decreased in the OS group, while CD8(+) cells were significantly increased (P < 0.05). The PDCD2 protein levels were markedly lower than that in the control group (P < 0.05). Additionally, PDCD2 was positively correlated with CD4(+) (R(2) = 0.66, P < 0.05), but was negatively correlated with CD8(+) (R(2) = -0.94, P < 0.05). Moreover, the cell viability and invasion ability were significantly higher than that in the control group and the NS siRNA group after transfection with PDCD2 siRNA (P < 0.05).
CONCLUSION: These results suggest that PDCD2 is involved in the pathogenesis of OS, and PDCD2 may play an important role in tumor suppression. These mechanisms might be related to immune response induced by CD4(+) and CD8(+) T cells.

Entities:  

Keywords:  CD4+; CD8+; Osteosarcoma; programmed cell death 2

Mesh:

Substances:

Year:  2015        PMID: 26617804      PMCID: PMC4637619     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

Review 1.  CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

Authors:  P A Cohen; L Peng; G E Plautz; J A Kim; D E Weng; S Shu
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

2.  Programmed cell death ligand 1 expression in osteosarcoma.

Authors:  Jacson K Shen; Gregory M Cote; Edwin Choy; Pei Yang; David Harmon; Joseph Schwab; G Petur Nielsen; Ivan Chebib; Soldano Ferrone; Xinhui Wang; Yangyang Wang; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Immunol Res       Date:  2014-04-21       Impact factor: 11.151

3.  PDCD2 is essential for inner cell mass development and embryonic stem cell maintenance.

Authors:  Weipeng Mu; Robert J Munroe; Anna K Barker; John C Schimenti
Journal:  Dev Biol       Date:  2010-09-09       Impact factor: 3.582

Review 4.  Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.

Authors:  James C Wittig; Jacob Bickels; Dennis Priebat; James Jelinek; Kristen Kellar-Graney; Barr Shmookler; Martin M Malawer
Journal:  Am Fam Physician       Date:  2002-03-15       Impact factor: 3.292

Review 5.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

Review 6.  Primary bone osteosarcoma in the pediatric age: state of the art.

Authors:  Alessandra Longhi; Costantino Errani; Massimiliano De Paolis; Mario Mercuri; Gaetano Bacci
Journal:  Cancer Treat Rev       Date:  2006-07-24       Impact factor: 12.111

Review 7.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

8.  Isolation and mapping of a human gene (PDCD2) that is highly homologous to Rp8, a rat gene associated with programmed cell death.

Authors:  T Kawakami; Y Furukawa; K Sudo; H Saito; S Takami; E Takahashi; Y Nakamura
Journal:  Cytogenet Cell Genet       Date:  1995

Review 9.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

10.  CD4 T cells and their role in antitumor immune responses.

Authors:  R E Toes; F Ossendorp; R Offringa; C J Melief
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  1 in total

1.  Identification of Key Genes Affecting Results of Hyperthermia in Osteosarcoma Based on Integrative ChIP-Seq/TargetScan Analysis.

Authors:  Yuxia Shi; Fan Yang; Shuqing Wei; Gang Xu
Journal:  Med Sci Monit       Date:  2017-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.